Tipifarnib and bortezomib are synergistic and overcome cell adhesion-mediated drug resistance in multiple myeloma and acute myeloid leukemia.

@article{Yanamandra2006TipifarnibAB,
  title={Tipifarnib and bortezomib are synergistic and overcome cell adhesion-mediated drug resistance in multiple myeloma and acute myeloid leukemia.},
  author={Niranjan Yanamandra and Nandita M Colaco and Nancy A Parquet and Robert William Buzzeo and David G. Boulware and Gabriela M Wright and Lia Elena Perez and William S Dalton and Darrin M. Beaupre},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2006},
  volume={12 2},
  pages={
          591-9
        }
}
It has been established in preclinical models of multiple myeloma and acute myeloid leukemia (AML) that the bone marrow microenvironment provides protection from chemotherapy- and death receptor-mediated apoptosis. This form of resistance, termed de novo drug resistance, occurs independent of chronic exposure to cancer-related therapies and likely promotes the development of multidrug resistance. Consequently, it is of major interest to identify compounds or drug combinations that can overcome… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 48 CITATIONS

Similar Papers

Loading similar papers…